Evidence map›Paper›PMID 37112680›Full record

ArticleVaccines2023

The SARS-CoV-2 Spike Protein Activates the Epidermal Growth Factor Receptor-Mediated Signaling.

Abdul Rasheed Palakkott, Aysha Alneyadi, Khalid Muhammad, Ali Hussein Eid, Khaled M A Amiri, Mohammed Akli Ayoub, Rabah Iratni

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Identification ofMolecules (Basel, Switzerland) · 2025
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Abdul Rasheed PalakkottDepartment of Biology, College of Science, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates.ORCID 0000-0002-5958-718X
Aysha AlneyadiDepartment of Biology, College of Science, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates.
Khalid MuhammadDepartment of Biology, College of Science, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates.ORCID 0000-0001-6488-1722
Ali Hussein EidDepartment of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar.ORCID 0000-0003-3004-5675
Khaled M A AmiriDepartment of Biology, College of Science, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates.ORCID 0000-0003-3240-2736
Mohammed Akli AyoubDepartment of Biology, College of Science, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates.ORCID 0000-0003-0022-578X
Rabah IratniDepartment of Biology, College of Science, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates.ORCID 0000-0003-2694-0378
United Arab Emirates University · AEKhalifa University of Science and Technology · AEQatar University · QA

Funding

United Arab Emirates University UAEU Research Office grant (RIMA-2020)
6 · The paper itself

Abstract

The coronavirus disease-19 (COVID-19) pandemic is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). At the molecular and cellular levels, the SARS-CoV-2 uses its envelope glycoprotein, the spike S protein, to infect the target cells in the lungs via binding with their transmembrane receptor, the angiotensin-converting enzyme 2 (ACE2). Here, we wanted to investigate if other molecular targets and pathways may be used by SARS-CoV-2. We investigated the possibility of the spike 1 S protein and its receptor-binding domain (RBD) to target the epidermal growth factor receptor (EGFR) and its downstream signaling pathway in vitro using the lung cancer cell line (A549 cells). Protein expression and phosphorylation were examined upon cell treatment with the recombinant full spike 1 S protein or RBD. We demonstrate for the first time the activation of EGFR by the Spike 1 protein associated with the phosphorylation of the canonical Extracellular signal-regulated kinase1/2 (ERK1/2) and AKT kinases and an increase in survivin expression controlling the survival pathway. Our study suggests the putative implication of EGFR and its related signaling pathways in SARS-CoV-2 infectivity and COVID-19 pathology. This may open new perspectives in the treatment of COVID-19 patients by targeting EGFR.

Indexed as

cancerCOVID-19EGFRhijackingSARS-CoV-2signalingSpike

Identifiers

PMID37112680
PMCPMC10141239
OpenAlexW4361273981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.